60 Degrees Pharmaceuticals, Inc. (SXTP)

0.9164 -0.04 (-4.17%) USD  |  NASDAQ  |  Nov 05, 16:00
0.8857 -0.03 (-3.35%) After-Hours: 20:00
More

60 Degrees Pharmaceuticals SG&A Expense (TTM) : 6.600M for June 30, 2026

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2021. Start Trial.
Date Value
June 30, 2026 6.600M
March 31, 2026 6.483M
December 31, 2025 6.280M
September 30, 2025 6.411M
June 30, 2025 6.119M
March 31, 2025 5.636M
December 31, 2024 5.025M
September 30, 2024 5.110M
June 30, 2024 5.209M
Date Value
March 31, 2024 4.542M
December 31, 2023 4.242M
September 30, 2023 2.965M
June 30, 2023 1.826M
March 31, 2023 1.626M
September 30, 2022 0.8515M
March 31, 2022 0.4379M
December 31, 2021 0.2632M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Harrow, Inc. 175.69M
ANI Pharmaceuticals, Inc. 324.76M
Corcept Therapeutics, Inc. 432.49M
Veru, Inc. 16.05M
Johnson & Johnson 25.50B